Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Yang AR, Yi HS, Warnock KT, Mamczarz J, June HL Jr, Mallick N, Krieter PA, Tonelli L, Skolnick P, Basile AS, June HL Sr.

Alcohol Clin Exp Res. 2012 May;36(5):863-73. doi: 10.1111/j.1530-0277.2011.01671.x. Epub 2011 Dec 7.

2.

Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.

McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS.

Alcohol Clin Exp Res. 2007 Nov;31(11):1866-71. Epub 2007 Sep 26.

PMID:
17908267
3.

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):857-73. Epub 2006 Apr 25.

PMID:
16636898
4.

The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.

Prins J, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Olivier B, Korte SM.

Pharmacol Biochem Behav. 2011 Jan;97(3):444-52. doi: 10.1016/j.pbb.2010.10.001. Epub 2010 Oct 8.

PMID:
20934452
5.

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Caldarone BJ, Paterson NE, Zhou J, Brunner D, Kozikowski AP, Westphal KG, Korte-Bouws GA, Prins J, Korte SM, Olivier B, Ghavami A.

J Pharmacol Exp Ther. 2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23.

6.

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.

7.

"Broad spectrum" antidepressants: is more better for the treatment of depression?

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Life Sci. 2003 Nov 7;73(25):3175-9. Review.

PMID:
14561522
8.

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.

Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A.

CNS Drug Rev. 2006 Summer;12(2):123-34. Review.

9.

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104.

PMID:
12586204
10.

The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.

Prins J, Denys DA, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Groenink L, Olivier B, Korte SM.

Eur J Pharmacol. 2010 May 10;633(1-3):55-61. doi: 10.1016/j.ejphar.2010.02.009. Epub 2010 Feb 12.

PMID:
20153745
11.

Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.

De Vry J, Maurel S, Schreiber R, de Beun R, Jentzsch KR.

Eur Neuropsychopharmacol. 1999 Dec;9(6):461-8.

PMID:
10625112
12.

The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.

Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, Schreiber R, Hanania T, Snoeren EM, Waldinger M, Olivier B.

Eur Neuropsychopharmacol. 2008 Dec;18(12):908-16. doi: 10.1016/j.euroneuro.2008.07.011. Epub 2008 Sep 11.

PMID:
18789657
13.
14.

Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats.

Hargreaves GA, McGregor IS.

Alcohol Clin Exp Res. 2007 Nov;31(11):1900-7. Epub 2007 Sep 14.

PMID:
17877781
15.

Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake.

Besheer J, Grondin JJ, Cannady R, Sharko AC, Faccidomo S, Hodge CW.

Biol Psychiatry. 2010 May 1;67(9):812-22. doi: 10.1016/j.biopsych.2009.09.016. Epub 2009 Nov 7.

16.

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.

Beer B, Stark J, Krieter P, Czobor P, Beer G, Lippa A, Skolnick P.

J Clin Pharmacol. 2004 Dec;44(12):1360-7.

PMID:
15545306
17.

Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism.

Tizabi Y, Getachew B, Rezvani AH, Hauser SR, Overstreet DH.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):398-402. doi: 10.1016/j.pnpbp.2008.09.010. Epub 2008 Sep 19.

18.

Increased operant responding for ethanol in male C57BL/6J mice: specific regulation by the ERK1/2, but not JNK, MAP kinase pathway.

Faccidomo S, Besheer J, Stanford PC, Hodge CW.

Psychopharmacology (Berl). 2009 May;204(1):135-47. doi: 10.1007/s00213-008-1444-9. Epub 2009 Jan 6.

19.

Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats.

Verplaetse TL, Rasmussen DD, Froehlich JC, Czachowski CL.

Alcohol Clin Exp Res. 2012 May;36(5):881-6. doi: 10.1111/j.1530-0277.2011.01653.x. Epub 2011 Oct 7.

20.

The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol.

June HL, McCane SR, Zink RW, Portoghese PS, Li TK, Froehlich JC.

Psychopharmacology (Berl). 1999 Nov;147(1):81-9.

PMID:
10591872
Items per page

Supplemental Content

Write to the Help Desk